XML Print

Background: Some resources have suggested that genetically inactivated PTs bear a more protective effect than chemically inactivated products. This study aimed to produce new version of PT, by cloning an inactive PTS1 in a fusion form with N-terminal half of the LLO pore-forming toxin. Methods: Deposited pdb structure file of the PT was used to model an extra disulfide bond. Codon-optimized ORF of the PTS1 was used to make recombinant constructs of PTS1 and LLO-PTS1 in the pPSG-IBA35 vector. The recombinant PTS1 and LLO-PTS1 proteins were expressed in BL21 DE3 and SHuffle T7 strains of E. coli and purified by affinity chromatography. Cytotoxic effects of the recombinant proteins were examined in the MCF-7 cell line. Results: The purity of the products proved to bemore than 85%. The efficiency of the disulfide bond formation in SHuffle T7 strain was higher than BL21 DE3 strain. No cytotoxicity of the recombinant proteins was seen in MCF-7 cells. Soluble recombinant PTS1 and LLO-PTS1 proteins were produced in SHuffle T7 strain of E. coli with high efficiency of disulfide bonds formation. Conclusion: The chimeric LLO-PTS1 with correct disulfide bonds was expressed  in E. coli successfully in SHuffle T7 strain Providing  the immunostimulatory effect of  LLO-PTS1, this chimeric protein would be a choice for the treatment and prevention of pertussis disease.
Type of Study: Full Length | Subject: Molecular Immunology & Vaccines

Add your comments about this article : Your username or Email:

© 2020 All Rights Reserved | Iranian Biomedical Journal

Designed & Developed by : Yektaweb